Y-mAbs Therapeutics, Inc. (YMAB)
NASDAQ: YMAB · Real-Time Price · USD
10.05
-0.49 (-4.65%)
Nov 21, 2024, 11:07 AM EST - Market open

Y-mAbs Therapeutics Revenue

Y-mAbs Therapeutics had revenue of $18.46M in the quarter ending September 30, 2024, a decrease of -9.74%. This brings the company's revenue in the last twelve months to $84.55M, down -8.99% year-over-year. In the year 2023, Y-mAbs Therapeutics had annual revenue of $84.82M with 29.96% growth.

Revenue (ttm)
$84.55M
Revenue Growth
-8.99%
P/S Ratio
5.49
Revenue / Employee
$845,530
Employees
100
Market Cap
450.13M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202384.82M19.55M29.96%
Dec 31, 202265.27M30.37M87.03%
Dec 31, 202134.90M14.15M68.18%
Dec 31, 202020.75M--
Dec 31, 2019---
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Esperion Therapeutics 295.45M
Treace Medical Concepts 202.86M
Arcturus Therapeutics Holdings 160.40M
GRAIL 117.67M
REGENXBIO 84.33M
Theravance Biopharma 63.19M
Zevra Therapeutics 24.49M
PureTech Health 468.00K
Revenue Rankings